Everest Medicines (HKG:1952) said China's 2026 National Reimbursement Drug List will include its ulcerative colitis drug Velsipity and antibiotic Xerava for the first time.
Velsipity, an oral treatment for adults with moderately to severely active ulcerative colitis, was approved by China's National Medical Products Administration in February 2026, according to a Monday Hong Kong bourse filing. Xerava, an intravenous antibiotic for complicated intra-abdominal infections in adults, received Chinese approval in March 2023 and was launched in July that year.
The updated reimbursement list will take effect on Jan. 1, 2027. The company's kidney disease drug Nefecon will also remain on the list.
Shares of the company rose over 1% in recent trade.
Comments